Actively Recruiting

Age: 18Years +
All Genders
ID01408225

Buckeye Surveillance, Contact, and Research for Multiple Myeloma and Amyloidosis

Led by Ohio State University Comprehensive Cancer Center · Updated on 2026-03-23

5000

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are studying patients with plasma cell diseases, including Multiple Myeloma and AL Amyloidosis, to improve their quality and length of life. They have created a database with patient information, blood samples, and bone marrow tissue to track treatments, their effectiveness, patient well-being, complications, remission duration, and overall survival. The study is observational and aims to support patients through information and clinical team access, as well as to develop better treatments. The study includes tissue banking, where samples are collected at diagnosis, during routine follow-up, or at relapse. This helps create a resource for research to understand these diseases better. The project covers surveillance, contact, and research, offering patients support and education about their condition and clinical trials. Participants will be contacted and followed over time to collect data on their treatments and health status. Researchers will monitor outcomes such as treatment responses and survival, while also providing information and support. The study aims to build a valuable resource for future research to reduce illness and death from these plasma cell disorders, with ongoing observation expected for up to three years.

CONDITIONS

Brief Title

Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosis of a plasma cell dyscrasia
Not Eligible

You will not qualify if you...

  • Prisoners are excluded from participation as they have no standard access to the Ohio State myeloma clinic and would impede the research objective of this protocol.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Surveillance

Duration - Up to 3 years

Participants are contacted and observed over time for research and surveillance purposes related to plasma cell disorders.

Visits occur during routine follow-up and at times of diagnosis or relapse for tissue collection

Trial Site Locations

Total: 1 location

1

Ohio State University Medical Center

Columbus, Ohio, United States, 43210

Actively Recruiting

Loading map...

Research Team

T

The Ohio State University Comprehensive Cancer Center

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Similar Trials

A Phase II Trial Evaluating 18F-Fluciclovine PET/CT in Multi...

Multiple Myeloma

Actively Recruiting

1 location

Early Phase I Evaluation of 64Cu-LLP2A for Imaging Hematolog...

Multiple Myeloma

Actively Recruiting

1 location

A Physician & Patient-powered Cohort Registry for Multiple M...

Multiple Myeloma

Actively Recruiting

27 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Published Research Related To This Trial

MiR-16 regulates crosstalk in NF-κB tolerogenic inflammatory signaling between myeloma cells and bone marrow macrophages.

Jihane Khalife, Jayeeta Ghose, Marianna Martella...

https://pubmed.ncbi.nlm.nih.gov/31593552